Akcea Completes Enrollment in Phase 2b Study of

AKCEA-APO(a)-LRx for high Lp(a)


CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-LRx. Akcea is conducting the study in patients with high Lp(a) and established cardiovascular disease (CVD) to determine the dose level and frequency of administration for a future planned Phase 3 cardiovascular outcome study and to determine the safety and tolerability profile of AKCEA-APO(a)-LRx. Akcea plans to report top-line data from the Phase 2b study in the second half of 2018. Akcea is an affiliate of Ionis Pharmaceuticals Inc. focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. 


Stroke and Lipoprotein(a)

Young, Fit Football Player Suffering

a Massive Stroke

Justin's Story

more here

Heart Attack and Lipoprotein(a)

   Young, Fit, Female Having A Heart Attack

Sandra's Story


more here

Aortic Stenosis and Lipoprotein(a)

Young, Pregnant having a Heart Attack, Bypass and Valve Replacement Surgery

Tiffany's Story

more here

Media enquiries, please contact 650-995-3242 or serevill@lipoproteinafoundation.org to find out more about Lp(a).








The upcoming calendar is currently empty.

Click here to view past events and photos »

Include these hashtags to spread the word about Lp(a): #REVEALpa   #TESTLpa

Tweet to us @LipoproteinaFDN

© 2016 The Lipoprotein(a) Foundation. The Lipoprotein(a) Foundation has received the State of California 501(c)(3) tax-exempt organization status and the Federal tax-exempt status EIN: 46-3024812. The information on this website is not intended to serve as or replace medical advice. 

Lipid Living Room, Lipid Buddy and Lipids Behaving Badly, and Cardiovascular Strong are trademarks of The Lipoprotein(a) Foundation.

Terms and Conditions

Privacy Policy



809 Laurel Street #460
San Carlos, CA 94070